Natesto intranasal testosterone developer Trimel Pharmaceuticals Corporation has announced that it has a new name: Acerus Pharmaceuticals Corporation.
Acerus President and CEO Tom Rossi commented, “We are very excited to officially launch our new corporate identity with a name that aligns to our Company’s value proposition. The name Acerus is derived from the Latin root word acer, and conveys sharp minds and passionate, spirited action as embodied by our current leadership team, employees and partners. Acer is also the genus of trees commonly known as the maple, the official tree and symbol of Canada.”
Endo acquired the US and Mexican rights to Natesto in November 2014. Acerus is also developing an intranasal testosterone for the treatment of anorgasmia in women.
Read the Acerus press release.
